Should I buy or sell P3 Health Partners stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for P3 Health Partners in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PIII shares. View PIII analyst ratings or view top-rated stocks .

What is P3 Health Partners' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for P3 Health Partners' shares. Their PIII share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 338.6% from the stock's current price. View analysts price targets for PIII or view top-rated stocks among Wall Street analysts .

How have PIII shares performed in 2023?

P3 Health Partners' stock was trading at $1.84 on January 1st, 2023. Since then, PIII stock has decreased by 38.0% and is now trading at $1.14. View the best growth stocks for 2023 here .

When is P3 Health Partners' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our PIII earnings forecast .

How were P3 Health Partners' earnings last quarter?

P3 Health Partners Inc. (NASDAQ:PIII) announced its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.11. The firm earned $288.35 million during the quarter, compared to analysts' expectations of $286 million. P3 Health Partners had a negative net margin of 10.73% and a positive trailing twelve-month return on equity of 2,454.69%.

Who are P3 Health Partners' major shareholders?

P3 Health Partners' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ameriprise Financial Inc. (1.74%), FMR LLC (0.76%), Emfo LLC (0.32%), GSA Capital Partners LLP (0.03%), Principal Financial Group Inc. (0.03%) and PNC Financial Services Group Inc. (0.02%). Insiders that own company stock include Atul Kavthekar, Michael Balkin , Pacific Founders Ugp Chicago, Pacific Founders Ugp I Chicago and Sherif Abdou. View institutional ownership trends .

How do I buy shares of P3 Health Partners?

Shares of PIII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

P3 Health Partners Stock Price, News & Analysis (NASDAQ:PIII)

$1.16

-0.04 (-2.92%)

(As of 02:40 PM ET)

Compare

Today's Range: $1.13
▼
$1.20
50-Day Range: $1.14
▼
$1.90
52-Week Range: $0.70
▼
$5.56

Volume: 175,563 shs
Average Volume: 425,436 shs
Market Capitalization: $364.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

P3 Health Partners MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 338.6% Upside
$5.00 Price Target
Short Interest: Bearish
7.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.98) to ($0.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

640th out of 949 stocks

Health Services Industry

6th out of 12 stocks

3.3

Analyst's Opinion

Consensus Rating
P3 Health Partners has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, P3 Health Partners has a forecasted upside of 338.6% from its current price of $1.14.
Amount of Analyst Coverage
P3 Health Partners has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.20% of the float of P3 Health Partners has been sold short.
Short Interest Ratio / Days to Cover
P3 Health Partners has a short interest ratio ("days to cover") of 7.3.
Change versus previous month
Short interest in P3 Health Partners has recently increased by 0.86%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
P3 Health Partners does not currently pay a dividend.
Dividend Growth
P3 Health Partners does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PIII.

3.3

News and Social Media Coverage

News Sentiment
P3 Health Partners has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for P3 Health Partners this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for PIII on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, P3 Health Partners insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,002,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.06% of the stock of P3 Health Partners is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.57% of the stock of P3 Health Partners is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for P3 Health Partners are expected to grow in the coming year, from ($0.98) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of P3 Health Partners is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of P3 Health Partners is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
P3 Health Partners has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About P3 Health Partners Stock (NASDAQ:PIII)

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

PIII Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PIII Stock News Headlines

November 15, 2023 | markets.businessinsider.com

Positive Revenue Prospects and Improved Cash Flow: Reasons Behind David Larsen’s Buy Rating for P3 Health Partners

November 12, 2023 | finance.yahoo.com

P3 Health Partners Inc. (NASDAQ:PIII) Q3 2023 Earnings Call Transcript

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

November 8, 2023 | businesswire.com

55,508

November 8, 2023 | finance.yahoo.com

P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results

November 3, 2023 | finance.yahoo.com

P3 Health Partners Schedules Third-Quarter 2023 Earnings Release and Conference Call

October 29, 2023 | finance.yahoo.com

Several Insiders Invested In P3 Health Partners Flagging Positive News

October 20, 2023 | money.usnews.com

P3 Health Partners Inc - Ordinary Shares - Class A

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

October 6, 2023 | uk.investing.com

P3 Health Partners Recent Insider Activity

October 4, 2023 | benzinga.com

P3 Health Partners 10% Owner Trades $186K In Company Stock

October 4, 2023 | benzinga.com

Massive Insider Trade At P3 Health Partners

September 14, 2023 | finance.yahoo.com

Chicago Pacific Founders UGP III, LLC Buys 270,000 Shares of P3 Health Partners Inc

September 12, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on P3 Health Partners (PIII)

September 10, 2023 | seekingalpha.com

P3 Health Partners: Right Place, Right Time, Wrong Horse To Back?

September 1, 2023 | msn.com

BTIG Initiates Coverage of P3 Health Partners Inc - (PIII) with Buy Recommendation

August 8, 2023 | finance.yahoo.com

At US$2.14, Is P3 Health Partners Inc. (NASDAQ:PIII) Worth Looking At Closely?

July 28, 2023 | finance.yahoo.com

P3 Health Partners Schedules Second-Quarter 2023 Earnings Release and Conference Call

July 19, 2023 | finance.yahoo.com

A Look At The Fair Value Of P3 Health Partners Inc. (NASDAQ:PIII)

July 10, 2023 | benzinga.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating P3 Health Partners Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

July 6, 2023 | msn.com

P3 Health Partners Inc - (PIII) Price Target Decreased by 15.38% to 5.61

June 15, 2023 | seekingalpha.com

P3 Health Partners On Solid Path To Profitability

June 9, 2023 | seekingalpha.com

P3 Health Partners: Just Another SPAC-Listed 'Value-Based Care' Company?

June 1, 2023 | msn.com

Why Shares of P3 Health Partners Soared This Week

May 17, 2023 | benzinga.com

Chief Executive Officer At This Health Care Company Buys $284K of Stock

May 17, 2023 | msn.com

Why P3 Healthcare Shares Jumped Wednesday

May 16, 2023 | finance.yahoo.com

P3 Health Partners Inc. (NASDAQ:PIII) Q1 2023 Earnings Call Transcript

See More Headlines

Receive PIII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for P3 Health Partners and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health services
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PIII
CUSIP: N/A
CIK: 1832511
Web: foresightacq.com
Phone: 702-910-3950
Fax: N/A
Employees: 600
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +316.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2,260.6599)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-270,130,000.00
Net Margins: -10.73%
Pretax Margin: -54.92%
Return on Equity: 2,454.69%
Return on Assets: 37.99%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 0.67
Quick Ratio: 0.67

Sales & Book Value

Annual Sales: $1.18 billion
Price / Sales: 0.32
Cash Flow: $40.00 per share
Price / Cash Flow: 0.03
Book Value: $0.60 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 313,089,000
Free Float: 259,676,000
Market Cap: $375.71 million
Optionable: Not Optionable
Beta: 1.39

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Sherif Abdou F.A.C.E.P. (Age 62)
FACP, M.D., Co-Founder, CEO & Director
Comp: $7.1M
Dr. Amir Bacchus M.B.A. (Age 58)
M.D., Co-Founder, Chief Medical Officer & Director
Comp: $4.3M
Mr. Atul Kavthekar
CFO & Chief Accounting Officer
Mr. William Bettermann
Executive VP & COO
Mr. Devery Goodey
Senior Vice President of Technology
Ms. Karen Blomquist
Vice President of Investor Relations
Ms. Jessica Puathasnanon
Chief Legal Officer, General Counsel & Secretary
Roy Youngblood
Director of Compliance
Ms. Kassi Belz APR
Executive Vice President of Communications, Culture & Engagement
Ms. Lorie Glisson CPA
Florida Market President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PIII Stock Analysis - Frequently Asked Questions

Should I buy or sell P3 Health Partners stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for P3 Health Partners in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PIII shares.
View PIII analyst ratings or view top-rated stocks.
What is P3 Health Partners' stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month target prices for P3 Health Partners' shares. Their PIII share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 338.6% from the stock's current price.
View analysts price targets for PIII or view top-rated stocks among Wall Street analysts.
How have PIII shares performed in 2023?: P3 Health Partners' stock was trading at $1.84 on January 1st, 2023. Since then, PIII stock has decreased by 38.0% and is now trading at $1.14.
View the best growth stocks for 2023 here.
When is P3 Health Partners' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our PIII earnings forecast.

How were P3 Health Partners' earnings last quarter?: P3 Health Partners Inc. (NASDAQ:PIII) announced its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.11. The firm earned $288.35 million during the quarter, compared to analysts' expectations of $286 million. P3 Health Partners had a negative net margin of 10.73% and a positive trailing twelve-month return on equity of 2,454.69%.
Who are P3 Health Partners' major shareholders?: P3 Health Partners' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ameriprise Financial Inc. (1.74%), FMR LLC (0.76%), Emfo LLC (0.32%), GSA Capital Partners LLP (0.03%), Principal Financial Group Inc. (0.03%) and PNC Financial Services Group Inc. (0.02%). Insiders that own company stock include Atul Kavthekar, Michael Balkin, Pacific Founders Ugp Chicago, Pacific Founders Ugp I Chicago and Sherif Abdou.
View institutional ownership trends.
How do I buy shares of P3 Health Partners?: Shares of PIII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PIII) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial